NOVO NORDISK A/S

Type: Company

Name: NOVO NORDISK A/S (Novo Nordisk, Novo-Nordisk A S)

Nationality: Denmark

Web Address: http://www.novonordisk.com/

Fact Sheet: Fact Sheet for Novo Nordisk A/S

First reported 19 hours ago - Updated 10 hours ago - 2 reports

Novo Nordisk phase III a obesity trial with liraglutide 3 mg confirms weight loss

Novo Nordisk, a global healthcare company, has reported headline results from a 56-week double-blind phase III a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight ... [Published PharmaBiz - 10 hours ago]

Entities: Obesity, Weight Loss, Placebo, NOVO NORDISK A/S

First reported May 24 2013 - Updated May 24 2013 - 1 reports

New obesity drug could hit US market in 2014

Novo Nordisk's new obesity drug could hit the American market in late 2014, adding competition as consumers and healthcare stakeholders seek to shrink U.S. waistlines.The Danish drug company said Thursday that its injectable liraglutide treatment resulted ... [Published The Hill - May 24 2013]

Entities: Obesity, Drugs, Qsymia

First reported May 23 2013 - Updated May 24 2013 - 12 reports

NOVO NORDISK A/S

Novo Nordisk A/S Says Obesity Drug Trial Confirms Weight Loss

I Novo Nordisk today announced the headline results from a 56-week double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with comorbidities ... [Published BioSpace - May 24 2013]

Entities: NOVO NORDISK A/S, Weight Loss, Obesity

First reported May 24 2013 - Updated May 24 2013 - 1 reports

One person dies from diabetes every 10 seconds

Called UNITE FOR Diabetes Philippines, the coalition developed the “Philippine Practice Guidelines on the Diagnosis and Management of Diabetes Mellitus,” which reflect current best practices and include local data. The guidelines are intended for all ... [Published Philippine Daily Inquirer - May 24 2013]

Entities: Diabetes, NOVO NORDISK A/S, Philippines, Pandemic, Insulin

First reported May 24 2013 - Updated May 24 2013 - 4 reports

Federal Reserve System

European Stocks Fall for Second Day as Investors Weigh Stimulus

May 24 (Bloomberg) -- European stocks fell for a second day as speculation that central banks will reduce stimulus measures overshadowed a bigger-than-forecast increase in U.S. durable- goods orders.Raiffeisen Bank International AG dropped 2.3 percent ... [Published La Repubblica - May 24 2013]

Entities: Haruhiko Kuroda, Chris Ford, Andrew Rummer, Federal Reserve System, State Street Global Advisors

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Allergan Inc

Allergan, Inc. (AGN), Dr. Reddy’s Laboratories Limited (ADR) (RDY): Should These Drug Companies Pay a Dividend?

Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination of a few companies in the drug manufacturing sector and my conclusions about their dividend ... [Published InsiderMonkey.com - May 24 2013]

Entities: Allergan Inc, Dividend, Drugs, New York Stock Exchange

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Natixis SA

Novo Nordisk Upgraded by Natixis to “Buy” (NVO)

Novo Nordisk (NYSE: NVO)A number of other firms have also recently commented on NVO. Analysts at Zacks reiterated a ?neutral? rating on shares of Novo Nordisk in a research note to investors on Friday, May 3rd. They now have a $181.00 price target on ... [Published American Banking News - May 24 2013]

Entities: NOVO NORDISK A/S, Natixis SA, New York Stock Exchange, Stocks

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Natixis Upgrades Novo Nordisk (NVO) to Buy

Natixis upgraded Novo Nordisk (NYSE: NVO) from Neutral to Buy.For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here. Shares of Novo Nordisk closed at $168.92 yesterday, with a 52 ... [Published Street Insider - May 24 2013]

Entities: NOVO NORDISK A/S, Natixis SA, iPad, iPhone

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Conversations About Sustainability In The Here-And-Now: Novo Nordisk Forges a New Path

Transparency generally comes in annual packages. Will Novo Nordisk's recently launched quarterly Triple Bottom Line (TBL) publication encourage conversations in the here-and-now?Submitted by: Elaine CohenTags: csr report, sustainability report, transparency, ... [Published CSR Wire - May 23 2013]

Entities: Sustainability, NOVO NORDISK A/S, Diabetes, iPad

First reported May 23 2013 - Updated May 23 2013 - 1 reports

BRIEF-Novo Nordisk reports headline results for liraglutide trial

4:49pm BSTSTOCKHOLM, May 23 (Reuters) - Novo Nordisk A/S : * Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesitytrial with liraglutide 3 mg * Link to statement ... [Published Reuters UK - May 23 2013]

Entities: NOVO NORDISK A/S, Weight Loss, Obesity

First reported May 23 2013 - Updated May 23 2013 - 1 reports

The Coming Diabetes Wars

War is brewing in the multibillion-dollar diabetes market. In particular, a major skirmish will soon be fought over which insulin products will emerge as victors in a changing landscape. How are the battle lines taking shape? Here's a quick overview.The ... [Published Motley Fool - May 23 2013]

Entities: Insulin, MannKind Corp, Lantus, NovoRapid, NOVO NORDISK A/S

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Novo Nordisk Says Completes Hemophilia Drug Trial

body: The results of a phase III trial of Novo Nordisk's N9-GP show that 99 percent of bleeding episodes in patients given the hemophilia drug were treated with just one infusion. The study also found that two-thirds of patients who were given N9-GP saw ... [Published AAPS Pharmceutica - May 23 2013]

Entities: Hemophilia, NOVO NORDISK A/S, Drugs, Patient

Quotes

Earlier this month, Eli Lilly halted development of Phase 3 candidate enzastaurin. The diffuse large B-cell lymphoma [dlbcl] drug "failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based chemotherapy." Although lousy data from enzastaurin is a kick in the pants for Eli Lilly, the company still has a promising oncology pipeline...

Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff [Published Seeking Alpha - 18 hours ago]

...are very pleased with the results of this trial,' said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "These data, together with previously reported phase 3 trials, consistently demonstrate clinically significant weight loss and improvements in obesity related risk factors in people with obesity."

Novo Nordisk Reports 8% Weight Loss in Phase 3a Obesity Trial with Liraglutide 3 mg [Published WebWire - May 24 2013]

More From BioPortfolio on "Edison Investment - Innate Pharma - New preclinical candidate - New anti-inflammatory and anti-cancer progress"

Edison Investment Innate Pharma New preclinical candidate New antiinflammatory and anticancer ... [Published BioPortfolio - May 24 2013]

"The study shows some good effects ... but whether that is enough to justify reimbursements, I am not sure" he said

UPDATE 1-Novo obesity drug could launch in U.S. end 2014 [Published CNBC - May 24 2013]

More Content

sort by: Date \| Relevance
Novo Nordisk phase III a obesity trial with lir... [Published PharmaBiz - 10 hours ago]
Diabetes And Oncology Might Cushion Eli Lilly's... [Published Seeking Alpha - 18 hours ago]
Novo Nordisk A/S (NVO) Says Obesity Drug Trial ... [Published BioSpace - 19 hours ago]
MODEL N INC: Model N to Present at the Raymond ... [Published 4 Traders - 19 hours ago]
Glencoe Grand Prix grows more grand [Published Glencoe News.com - 20 hours ago]
European stocks turn mostly lower, despite Germ... [Published Nasdaq - 21 hours ago]
New obesity drug could hit US market in 2014 [Published The Hill - May 24 2013]
Novo Nordisk A/S Says Obesity Drug Trial Confir... [Published BioSpace - May 24 2013]
Deals Of The Week Ponders When $2.1 Billion Is ... [Published The IN VIVO Blog - May 24 2013]
New Obesity Drug Could Launch in U.S. Before 2015 [Published InvestorPlace.com - May 24 2013]
One person dies from diabetes every 10 seconds [Published Philippine Daily Inquirer - May 24 2013]
European Stocks Fall for Second Day as Investor... [Published La Repubblica - May 24 2013]
Novo Nordisk Reports 8% Weight Loss in Phase 3a... [Published WebWire - May 24 2013]
Stock Upgrades: Changing Tides Makes Procter & ... [Published Nasdaq - May 24 2013]
Allergan, Inc. (AGN), Dr. Reddy’s Laboratories ... [Published InsiderMonkey.com - May 24 2013]
Star manager Born grows bullish on pharma [Published Citywire - May 24 2013]
European Stocks Decline for Second Day; Raiffei... [Published Washington Post - May 24 2013]
Edison Investment Innate Pharma New preclinic... [Published BioPortfolio - May 24 2013]
Novo Nordisk Upgraded by Natixis to “Buy” (NVO) [Published American Banking News - May 24 2013]
Natixis Upgrades Novo Nordisk (NVO) to Buy [Published Street Insider - May 24 2013]
New anti-inflammatory and anti-cancer progress [Published Stockopedia - May 24 2013]
European stocks mixed to higher, eyes on Ifo re... [Published Nasdaq - May 24 2013]
UPDATE 1-Novo obesity drug could launch in U.S.... [Published CNBC - May 24 2013]
Most European Stocks Climb Before U.S. Durable-... [Published Washington Post - May 24 2013]
Most European Stocks Climb Before U.S. Durable-... [Published La Repubblica - May 24 2013]
Novo sees US obesity drug launch end 2014/start... [Published Sharenet - May 24 2013]
Emisphere Technologies, Inc. (EMIS) - Pharmaceu... [Published Live-PR.com - May 24 2013]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: Br... [Published Proactiveinvestors United Kingdom RSS feed - May 24 2013]
Indian diabetes drug sparks controversy [Published Daily News TSN - May 23 2013]
Teva Pharmaceutical Industries Ltd (ADR) (TEVA)... [Published InsiderMonkey.com - May 23 2013]

Blogs

sort by: Date \| Relevance
Deals Of The Week Ponders When $2.1 Billion Is ... [Published The IN VIVO Blog - May 24 2013] With the oncology high season upon us and just about everyone in the industry scrambling to decode the secrets hidden in ASCO’s abstracts, we couldn’t help but stop and reflect on how at least one company got where it is in oncology today through stellar ...
Should Pharma Do Tumblr? [Published Pharma Marketing Blog - May 23 2013] Peter Houston (@Flipping_Pages) asked "Could Pharma Do Tumblr?" in a guest post to PharmExecBlog ( here ). "I’m not suggesting that anyone switch their social media budget to Tumblr today on the strength of Yahoo’s involvement," said Houston. "But it’s ...
Novo Nordisk reports positive results from Phas... [Published PBR - News - May 20 2013] Novo Nordisk has reported positive results from Phase-3 study of FIX derivative N9-GP to treat haemophilia B. ...
Novo Nordisk invests in Kalundborg plant for se... [Published PBR - News - May 08 2013] Novo Nordisk has announced the investment of additional DKK380m ($66.71m) in its Kalundborg plant in Denmark for the production of semaglutide. ...
Emisphere, Novo Nordisk amend Oral GLP-1 develo... [Published PBR - News - May 01 2013] Emisphere Technologies and Novo Nordisk have amended Oral GLP-1 receptor agonist development and license agreement. ...

Audio/Video

sort by: Date \| Relevance
FDA Won't Approve Novo Nordisk Insulin: Hot Trends [Published TheStreet.com - YouTube - Feb 12 2013]
The Top Ten Stocks for Monday, February 11 [Published Bloomberg - YouTube - Feb 11 2013]
Daily Digit: Novo Nordisk shares slide [Published Reuters Video: Business - Feb 11 2013]

Press Releases

sort by: Date \| Relevance
Novo Nordisk A/S : Novo Nordisk rapporterer 8% ... [Published GlobeNewswire: Acquisitions News - May 23 2013]
Novo Nordisk A/S : Novo Nordisk reports 8% weig... [Published GlobeNewswire: Acquisitions News - May 23 2013]
Novo Nordisk A/S : Novo Nordisk reports 8% weig... [Published Marketwire - Breaking News Releases - May 23 2013]
Novo Nordisk A/S - aktietilbagekøbsprogram [Published GlobeNewswire: Acquisitions News - May 21 2013]
Novo Nordisk A/S - Share repurchase programme [Published GlobeNewswire: Acquisitions News - May 21 2013]